OBJECTIVES: stem bark (ACSB) in metabolic dysfunction-associated steatotic liver disease (MASLD) induced by a high-fat and high-fructose (HFHFr) diet. METHODS: The HFHFr model was developed over 10 weeks. After six weeks of induction, ACSB was administered orally at 100 and 200 mg/kg for four weeks, while the standard group received pioglitazone (3 mg/kg). Biochemical, lipid, inflammatory, and histopathological parameters were evaluated. RESULTS: HFHFr administration produced significant alterations in lipid, biochemical, inflammatory, and liver function parameters, along with histopathological changes. ACSB treatment improved these alterations in a dose-dependent manner, with 200 mg/kg showing effects. CONCLUSIONS: ACSB demonstrated hepatoprotective and antihyperlipidemic effects against HFHFr-induced MASLD, potentially associated with its flavonoid and polyphenolic constituents.
No takes yet. Share an insight, caveat, or question.
Vhanale et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: